Media Articles Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
Hormones Might Offer Relief From Chronic Pain, Small Study Suggests
Source: Yahoo Health News [2014.03.08]
SATURDAY, March 8, 2014 (HealthDay News) -- A combination of two hormones might make a difference in reducing suffering in people with chronic pain, according to a small, preliminary study. Seven of 9 patients reported a 30 percent to 40 percent d...
Extra Weight Adds $$ to Chest Pain Treatment
Source: MedPage Today Cardiovascular [2014.03.06]
(MedPage Today) -- Among patients showing up in the emergency department with chest pain and dyspnea, those carrying extra weight tended to incur higher costs and have longer hospital stays, researchers found.
New research points to talking-therapy treatments to manage osteoarthritis pain
Source: Arthritis / Rheumatology News From Medical News Today [2014.03.05]
Scientists have shown for the first time that the abnormalities in the way the brain experiences pain may be to blame for the chronic pain suffered by osteoarthritis patients.
New approach to breast reconstruction surgery reduces opioid painkiller use, hospital stays
Source: Breast Cancer News From Medical News Today [2014.03.05]
A new approach to breast reconstruction surgery aimed at helping patients' bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found.
Researchers find link between chronic pain and heart disease
Source: Cardiovascular / Cardiology News From Medical News Today [2014.03.05]
Elderly people who have chronic muscle pain are at a significantly increased risk of having heart disease - researchers at Teesside University have found.Almost half of elderly people who have suffered chronic musculoskeletal pain (CMP) go on to suffer cardiovascular disease (CVD), researchers suggest.
Published Studies Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases] [2005.06]
CONCLUSION: Samarium-153 (Quadramet) is cost-effective in treating pain in patients with prostate cancer and bone metastases.
A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. [2003.04]
CONCLUSION: The data showed that the therapeutic efficacy of (153)Sm-EDTPM was higher than that of pamidronate disodium (for pain relief maintained more than 3 weeks) and its incidence of blood toxicity was also higher than that of pamidronate disodium. Copyright 2003 S. Karger AG, Basel
Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. [1999.01]
A multicentre trial was organized in China as part of an international coordinated research project to study the efficacy and toxicity of single-dose samarium-153 ethylene diamine tetramethylene phosphonate (EDTMP) as a palliative treatment for painful skeletal metastases... Further studies are needed to identify better ways of determining the appropriate dose in the individual case and the efficacy of treatment.
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. [1998.04]
PURPOSE: To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP) in a double-blind, placebo-controlled study... CONCLUSION: A single dose of 1.0 mCi/kg of 153Sm-EDTMP provided relief from pain associated with bone metastases. Pain relief was observed within 1 week of administration and persisted until at least week 16 in the majority of patients who responded.
Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases. [2011.10.01]
CONCLUSIONS: Our observation of new-onset, acute and transient edema and neuropathy after samarium Sm 153 lexidronam and of a relationship between edema and post-samarium Sm 153 lexidronam chemotherapy suggests the need for re-examination of patients in past series or for a prospective investigation with nonhematologic adverse events as a primary endpoint. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Quadramet (Samarium SM 153 Lexidronam Pentasodium)
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer [Recruiting]
- No treatment is known to improve survival for prostate cancer patients who have not
been helped by previous treatments with hormones and chemotherapy.
- An experimental vaccine called PSA/TRICOM contains genes for a protein produced by
prostate cancer cells called prostate-specific antigen (PSA). The vaccine can trigger
the immune system to make cells that may be able to recognize and attack the cancer
cells that make PSA.
- GM-CSF is an approved drug that is usually given to increase a patient's white blood
cell count or to stimulate the immune system.
- 153Sm-EDTMP is a radioactive drug that has been approved for many years to treat
advanced prostate cancer. It is given through a vein and can be targeted directly to
tumors in the bone where it can relieve pain caused by bone lesions. Radiation also
increases the level of certain proteins inside the tumor, making it easier for the
immune system to find and kill the tumor cells.
- When laboratory mice were given just vaccine, just radiation, or a combination of both,
the combination was most effective in treating tumors.
- To determine if combined treatment with PSA/TRICOM vaccine and 153Sm-EDTMP radiation can
delay progression of prostate cancer better than radiation alone.
- Patients who have advanced prostate cancer that has worsened despite treatments with
hormones, have two or more bone lesions related to their prostate cancer, and have had prior
treatment with docetaxel chemotherapy.
- Patients are randomly assigned to receive radiation alone (Arm A) or radiation with
vaccine and sargramostim (Arm B).
- Arm A receives 153Sm-EDTMP radiation starting on study day 8 and repeated every 12
- Arm B receives a priming vaccine on study day 1 and radiation on day 8. Radiation
therapy is repeated every 12 weeks. Boosting vaccines are given on days 15 and 29 and
then monthly. GM-CSF is given with each vaccination (on the day of the vaccination and
for the next 3 days) to enhance the immune response. Vaccinations and GM-CSF are given
as injections under the skin, usually in the thigh. Radiation therapy is given through
- Patients are monitored regularly with physical examinations, blood and urine tests, and
scans to evaluate safety and treatment response.
- Patients who are HLA-A2-positive undergo apheresis, a procedure similar to donating
blood, for obtaining immune cells called lymphocytes to measure the immune response to
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases [Recruiting]
- To determine the time to progression in subjects with breast cancer metastatic to bone
only treated with 153Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation
- To determine the overall survival at one year.
- To determine the efficacy of 153Sm-EDTMP at 6 months.
- To assess pain in subjects treated with 153Sm-EDTMP.
- To determine the safety of 153Sm-EDTMP.
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation
therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when
given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in
treating patients with relapsed or refractory multiple myeloma.
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain [Active, not recruiting]
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Zoledronic acid and pamidronate
may help relieve bone pain caused by multiple myeloma. Giving samarium Sm 153 lexidronam
pentasodium together with zoledronic acid or pamidronate may be an effective treatment for
PURPOSE: This phase I/II trial is studying the side effects and best dose of samarium Sm 153
lexidronam pentasodium when given together with zoledronic acid or pamidronate and to see how
well it works in treating patients with relapsed or refractory multiple myeloma and bone
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer [Recruiting]
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects
of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with
castrate metastatic prostate cancer.